Tagged with

Hong Kong Professor Samuel Au, Founder and CEO of Cornerstone Robotics, recounts his journey from business to academic research to building one of Asia’s most promising surgical robotics ventures. He explains how the Sentire® Surgical System is redefining precision, access, and training in operating rooms worldwide, combining Hong Kong’s innovation ecosystem with…

Hong Kong Drawing on over two decades of leadership industry across Asia, Cecilia Qi reflects her transition from global pharma to leading DCH Auriga. She shares insights on the company’s evolution into an integrated market management partner, the strategic role of Hong Kong, and the future of healthcare distribution in Asia. Agility…

LatAm Fernando Zarate, Vice President of Bausch Health’s Latin American operations, outlines the company’s strategic positioning across the region. With 35 years in the industry and nearly two decades at Bausch Health, he today oversees one of the top 15 companies in the LatAm market. Zarate sets out a vision to…

Taiwan Hung Lai Wu, Chairperson of the Taiwan Alliance of Patients’ Organisations (TAPO) and a home dialysis patient for 18 years, has transformed personal experience into systemic advocacy. Since becoming a member of the board of directors of TAPO in 2016, she has championed patient representation within Taiwan’s National Health Insurance…

Taiwan Cathy Su, General Manager for Taiwan, Hong Kong/Macau & Singapore at Gilead Sciences, reflects on her nineteen-year tenure with the biopharmaceutical company, progressing from market analytics to multi-market leadership. She discusses Gilead’s strategic evolution from virology specialist to diversified oncology player, the complexities of navigating diverse Asian healthcare systems, and…

Taiwan How leadership choices translate into lasting impact is the central theme of this conversation with Grant Hu. From reshaping Eisai Taiwan’s organisation to navigating access, innovation, and policy engagement, the interview examines how a focused affiliate can exert influence beyond its size. It also highlights Taiwan’s role in turning long-term…

Mexico Guy Savoir, CEO at Carnot Laboratorios, brings strategic vision to Mexico’s pharmaceutical reindustrialisation. Leading a company that has achieved balanced growth across Mexican and Latin American markets, he articulates an ambitious vision for North American pharmaceutical integration whilst navigating complex regulatory environments. Under his leadership, Carnot has committed 150 million…

Argentina Gustavo Pelizzari leads Elea, Argentina’s largest pharmaceutical company by sales volume, employing 1,350 people. Under his leadership, Elea has achieved the unique distinction of simultaneously leading both the retail pharmaceutical market and the high-cost speciality products segment, a feat that requires markedly different capabilities. Leveraging full vertical integration and a…

France Laurence Peyraut serves as Director General of LEEM (Les Entreprises du Médicament), France’s pharmaceutical industry association representing 270 companies ranging from small French generic manufacturers to major multinational innovators. With two years at LEEM and one year on the EFPIA Board, Peyraut is operating under unprecedented geopolitical pressures reshaping pharmaceutical…

France MaaT Pharma is entering a defining moment in its mission to bring microbiotherapies into areas of acute unmet need. Hervé Affagard recounts how a personal catalyst, an engineering mindset and early scientific partnerships shaped a platform now approaching its first potential approval for its first microbiome drug candidate. The journey…

France Estelle Fruchet, General Manager of Shionogi France since September 2024, brings 25 years of pharmaceutical experience spanning major organisations including Roche, Gilead, and Novartis Gene Therapies. A pharmacist by training with specialisation in product launches – most notably Gilead’s hepatitis C therapy – Estelle Fruchet now leads a 25-person affiliate…

Global 2025 was a year of volatility for pharma and healthcare. In particular, the speed with which the administration of Donald Trump makes (and often then changes) consequential policy decisions has left industry stakeholders in the US and globally scrambling to fall in line. There are already clear winners and losers…